MYOKARDIA,INC. (NASDAQ:MYOK) Files An 8-K Results of Operations and Financial ConditionItem 2.02Results of Operations and Financial Condition.
On August 7, 2017, MyoKardia, Inc. announced its financial results for the three and six months ended June 30, 2017. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in Item 2.02 of this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.
Item 2.02Financial Statements and Exhibits
Press Release issued by MyoKardia, Inc. on August 7, 2017, furnished herewith
MyoKardia Inc ExhibitEX-99.1 2 myok-ex991_7.htm EX-99.1 myok-ex991_7.htm Exhibit 99.1 MyoKardia Reports Second Quarter 2017 Financial Results and Operational Progress Company to Host Conference Call and Webcast Today at 8:30 a.m. EDT (5:30 a.m. PDT) Positive Topline Results in First Patient Cohort of Phase 2 PIONEER-HCM Study SOUTH SAN FRANCISCO,…To view the full exhibit click
About MYOKARDIA,INC. (NASDAQ:MYOK)
MyoKardia, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that results from biomechanical defects in cardiac muscle contraction. It is engaged in the business of developing and commercializing therapeutics. Its pipeline includes over four therapeutic programs for the chronic treatment of over two forms of heritable cardiomyopathy-hypertrophic cardiomyopathy (HCM), and dilated cardiomyopathy (DCM). Its lead product candidate, MYK-461, is an orally-administered small molecule that reduces cardiac muscle contractility leading to HCM. In preclinical models of HCM, MYK-461 has been shown to prevent and reverse disease progression and to reduce left ventricular outflow tract obstruction. It is evaluating MYK-461 in over three Phase I clinical trials, including approximately two single ascending dose (SAD) trials and over one multiple ascending dose (MAD) trial.